Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2015 - 20203

Settings

Author: search.filters.author.Eski, Erkansearch.filters.applied.f.language: search.filters.language.eng

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Effect of Nasal Packs in Septoplasty
    (2015) Eski, Erkan; Yilmaz, Ismail; 0000-0002-4784-3342; 0000-0002-1694-7608; 26052044; AAD-5458-2021; AAJ-2992-2021
  • No Thumbnail Available
    Item
    Do Probiotics Have A Role in the Treatment of Allergic Rhinitis? A Comprehensive Systematic Review and Meta-Analysis
    (2016) Guvenc, Isil Adadan; Muluk, Nuray Bayar; Mutlu, Fezan Sahin; Eski, Erkan; Altintoprak, Niyazi; Oktemer, Tugba; Cingi, Cemal; 0000-0002-4784-3342; S-2103-2016; AAD-5458-2021; AAA-1951-2021
    Objective: To investigate clinical evidence for the efficacy of probiotics in the treatment of allergic rhinitis (AR). Methods: A systematic search was conducted to review the results of all randomized, double-blind, placebo-controlled trials by following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement. Primary outcome measurements were total nasal and ocular symptom scores (SS) and quality of life (QoL) questionnaires. Secondary outcome measurements were individual nasal SS and immunologic parameters. Results: Twenty-two randomized, double-blind, placebo-controlled studies were included. Seventeen trials showed significant benefit of probiotics clinically, whereas eight trials showed significant improvement in immunologic parameters compared with placebo. All five studies with Lactobacillus paracasei (LP) strains demonstrated clinically significant improvements compared with placebo. Probiotics showed significant reduction in nasal and ocular SS (standardized mean difference [SMD], -1.23, p < 0.001; and SMD, -1.84, p < 0.001; respectively), total, nasal, and ocular QoL scores compared with placebo (SMD, -1.84, p < 0.001; SMD, -2.30, p = 0.006; and SMD, -3.11, p = 0.005; respectively). Although heterogeneity was high, in subgroup analysis, SMD for total nasal and ocular symptoms with patients with seasonal AR and for nasal QoL scores for studies with LP-33 strain were significant and homogenous. Scores of nasal blockage, rhinorrhea, and nasal itching were significantly lower in the probiotic group compared with placebo. The meta-analysis studies SS the Japanese guidelines revealed a significant, homogenous SMD score of -0.34 for individual nasal SS, above the minimal important clinical difference value of 0.3. The T-helper 1 to T-helper 2 ratio was significantly lower in the probiotic group compared with placebo (SMD, -0.78; p = 0.045). Conclusion: Despite high variability among the studies, synthesis of available data provided significant evidence of beneficial clinical and immunologic effects of probiotics in the treatment of AR, especially with seasonal AR and LP-33 strains. With the rising pool of studies, the most promising strains in specific allergies can be revealed and adjuvant therapy with probiotics can be recommended for the treatment of AR.
  • No Thumbnail Available
    Item
    Comparing the Efficiencies of Hyperbaric Oxygen Therapy and Intratympanic Steroid Treatment for Sudden Hearing Loss
    (2020) Eski, Erkan; Babakurban, Seda; Yilmaz, Serkan; Yilmazer, Cuneyt; Erkan, Alper Nabi; Caylakli, Fatma; Yilmaz, Ismail; 0000-0002-4784-3342; 0000-0001-5067-4044; 0000-0002-7333-2896; 0000-0001-7138-1400; 32784167; AAD-5458-2021; AAI-8856-2021; AAP-7195-2020; H-1063-2019
    OBJECTIVES: To compare the efficiencies of hyperbaric oxygen therapy (HBOT) and intratympanic steroid (ITS)treatment for idiopathic sudden sensonneural hearingloss (ISSHL). MATERIALS and METHODS: A total of 136 patients who were treated for ISSHL were reviewed fromthemedical records. All of the patients were given systemic steroid therapy (SST). Among them,33patients received HBOT and 36 patients received ITS treatment following SST. The starting time to treatment, risk factors, hearing level, hearing gain (HG), and recovery rate were evaluated from retrospectiverecords. RESULTS: No substantial change in HG was observed for either the HBOT or ITS treatment cohort (p>0.05). But the time to recovery was higher in the ITS treatment cohort (40%) than in theHBOT cohort (17%). The starting time to ITS treatment was 4 days (range: 1-30) and that to HBOT was 8 days (range:3-30). There was a significant difference in the starting time to treatment (Mann-Whitney U-test, p=0.043). Also, hearing loss in the HBOT group was significantly higher than in the ITS treatment group. A significant difference was observed before and after ITS treatment (p<0.05). CONCLUSION: In patients compared with late-onset treatment, ITS may be more effective than HBO after SST failure. It can be used as salvage therapy in patients with ISSHL who are unresponsive to a primary systemic steroid. We observed that HBOT didnot improve results when it was started late. Therefore, more studies that include both ITS treatment and HBOTas anearly treatment option are needed.